报价延迟最少15分钟:2025/07/18 15:10 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
67.97 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.20/6.91
|
|
企业价值
13.38B
|
| 资产负债 |
|
每股账面净值
18.95
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
4.24B
|
|
每股收益
18.64
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/18 15:10 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
